Clinical trials: Gastric (Stomach) Cancer
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma
Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line therapy.
- Trial name
- mSOX (NCT01552980)
- Testing
- S-1 and Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect
Study of Comparing of With and Without Sequential Therapy of S-1
The goal of this single arm clinical trial is to learn about sequential S-1 adjuvant therapy in patient wich locally advanced gastric cancer.
- Trial name
- NCT05813015
- Testing
- Docetaxel, Tegafur-Gimeracil-Oteracil
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Adenocarcinoma
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
- Trial name
- NCT01253525
- Testing
- Ramucirumab (IMC-1121B ), Paclitaxel
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Gastric Cancer
Omentectomy for Metabolic Syndrome in Gastric Cancer Patients
Many features of the metabolic syndrome are associated with insulin resistance. And, metabolic syndrome and insulin resistance are related to visceral obesity.
- Trial name
- NCT02641925
- Testing
- Omentum preserving, Total omentectomy
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Keimyung University Dongsan Medical Center
Gastric Adenocarcinoma
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric…
- Trial name
- NCT02862535
- Testing
- Andecaliximab, S-1, Cisplatin
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Colorectal Cancer, Gallbladder Cancer
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
RATIONALE: Diagnostic procedures, such as visceral lymphatic mapping using isosulfan blue, may help find cancer of the pancreas, colon, stomach, small intestine, or gallbladder and find out how far the disease has spread.
- Conditions
- Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00489515
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Wake Forest University Health Sciences
Gastrostomy, Gastric
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
- Conditions
- Gastrostomy, Gastric, GastroEsophageal Cancer
- Trial name
- NCT05205343
- Testing
- Standard of Care, Control Group
- Where
- 4 sites in United States, Japan and 1 more
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Apatinib Combined, SOX
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced…
- Conditions
- Apatinib Combined, SOX, Neoadjuvant Therapy, Locally Advanced Gastric Cancer
- Trial name
- NCT03192735
- Testing
- ApatinibMesylateTablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chang-Ming Huang, Prof.
Gastric Cancer, Diabetes Mellitus, Type 2
Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery
This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with…
- Trial name
- STARDOM (NCT04284943)
- Testing
- Long limb Roux-en-Y reconstruction after subtotal gastrectomy, Conventional Roux-en-Y reconstruction after subtotal gastrectomy, Billroth II reconstruction after subtotal gastrectomy
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Korea University Anam Hospital
Gastric Cancer
Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer
Helicobacter pylori (H. pylori) is associated with gastric cancer in epidemiological studies.Gastric atrophy and intestinal metaplasia caused by H. pylori are considered as precancerous lesions, but whether H.
- Trial name
- NCT01002443
- Testing
- Helicobacter pylori eradication
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- National Cancer Center, Korea
Stomach Neoplasms
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
- Trial name
- NCT02485015
- Testing
- Cytokine-Induced Killer Cells, Apatinib
- Volunteers
- 80 people
- Sponsor
- The First People's Hospital of Changzhou
Stomach Cancer
A Study of Vinflunine in Patients With Gastric Cancer
The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer in patients with advanced or metastatic stomach cancer who have progressed on a prior treatment with a fluoropyrimidine or…
- Trial name
- NCT00359476
- Testing
- Vinflunine
- Where
- 6 sites in Malaysia, Philippines and 1 more
- Volunteers
- 55 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who…
- Trial name
- NCT01224652
- Testing
- Paclitaxel, Irinotecan
- Where
- 2 sites in South Korea
- Volunteers
- 518 people
- Sponsor
- Korean Cancer Study Group
Gastric Neoplasms, Gastric Cancer
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric…
- Conditions
- Gastric Neoplasms, Gastric Cancer, Gastric Lesion
- Trial name
- NCT05551416
- Testing
- Identification of risk factors, Characterization of premalignant gastric lesions, Identification of biomarkers
- Where
- 15 sites in Spain
- Volunteers
- 1,200 people
- Sponsor
- EDUARDO ALBENIZ
Gastric Cancer
Postoperative Chemoradiotherapy With S-1 in Gastric Cancer
This study was conducted to evaluate the clinical outcomes and toxicities of adjuvant treatment including S-1/cisplatin chemotherapy followed by S-1 based CRT.
- Trial name
- NCT01824004
- Testing
- S-1
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Chonnam National University Hospital
Gastric Cancer
Effect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided Analgesia
The primary purpose of this study is to investigate the effect of pneumoperitoneum on remifentanil requirements in the surgical pleth index-guided analgesia for laparoscopic gastrectomy.
- Trial name
- NCT03788447
- Testing
- High end-tidal CO2, Low CO2 group
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Ajou University School of Medicine
Gastric Cancer, Gastroesophageal Cancer
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
The purpose of this study is to evaluate the efficacy and safety of the study drug known as KH903 in participants with gastric and gastroesophageal cance
- Trial name
- NCT04555304
- Testing
- KH903 + Paclitaxel
- Volunteers
- 81 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Esophagus Cancer, Stomach Cancer
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity.
- Conditions
- Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer
- Trial name
- FluoHeart (NCT02216149)
- Testing
- S-1, Capecitabine, Oxaliplatin
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Heikki Joensuu
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.